• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcmPermissionsJournals.ASM.orgJournalJCM ArticleJournal InfoAuthorsReviewers
J Clin Microbiol. Sep 1996; 34(9): 2053–2057.
PMCID: PMC229189

Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents.

Abstract

An enzyme-linked immunosorbent assay (ELISA) to detect antibodies to Escherichia coli O157 lipopolysaccharide (LPS) was developed with sera from 63 children with confirmed recent E. coli O157 infection and from 256 age-stratified urban controls. The median ELISA values for control and case sera were 0.05 (interquartile range, 0 to 0.20; mean +/- standard deviation [SD], 0.15 +/- 0.22) and 1.41 (interquartile range, 1.11 to 1.59; mean +/- SD, 1.41 +/- 0.53), respectively (P < 0.001). With a breakpoint of 0.59 (mean ELISA value of the control sera + 2 SDs), the assay had a sensitivity, specificity, and positive and negative predictive values of 95, 94, 80, and 98%, respectively, for recent E. coli O157 infection. The O157 LPS assay and Vero cytotoxin (VT) 1-neutralizing-antibody (NAb) assay were used to compare the relative frequencies of O157 LPS antibodies and VT1-NAbs in an age-stratified urban population from Toronto, Ontario, Canada, and in 216 healthy family members from dairy farm in southern Ontario. The frequency of O157 LPS antibodies was about threefold higher in dairy farm residents (12.5%) than in urban residents (4.7%) (P < 0.01). Similarly, the frequency of VT1-NAbs was about sixfold higher in dairy farm residents (42.0%) than in urban residents (7.7%) (P < 0.001). These findings are consistent with a greater level of exposure of dairy farm residents to VT-producing E. coli (VTEC) strains. The high rate of seropositivity to VT1 in farm residents probably reflects the booster effect of repeated VTEC exposures and argues against a sustained generalized immunosuppressive effect of VT1. Seroepidemiological studies may help in assessing the level of exposure of different populations to VTEC strains.

Full Text

The Full Text of this article is available as a PDF (196K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ashkenazi S, Cleary TG, Lopez E, Pickering LK. Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome. J Pediatr. 1988 Dec;113(6):1008–1014. [PubMed]
  • Bitzan M, Karch H. Indirect hemagglutination assay for diagnosis of Escherichia coli O157 infection in patients with hemolytic-uremic syndrome. J Clin Microbiol. 1992 May;30(5):1174–1178. [PMC free article] [PubMed]
  • Bitzan M, Ludwig K, Klemt M, König H, Büren J, Müller-Wiefel DE. The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a Central European, multicentre study. Epidemiol Infect. 1993 Apr;110(2):183–196. [PMC free article] [PubMed]
  • Caprioli A, Luzzi I, Rosmini F, Pasquini P, Cirrincione R, Gianviti A, Matteucci MC, Rizzoni G. Hemolytic-uremic syndrome and Vero cytotoxin-producing Escherichia coli infection in Italy. The HUS Italian Study Group. J Infect Dis. 1992 Jul;166(1):154–158. [PubMed]
  • Chart H, Okubadejo OA, Rowe B. The serological relationship between Escherichia coli O157 and Yersinia enterocolitica O9 using sera from patients with brucellosis. Epidemiol Infect. 1992 Feb;108(1):77–85. [PMC free article] [PubMed]
  • Chart H, Rowe B. Improved detection of infection by Escherichia coli O157 in patients with haemolytic uraemic syndrome by means of IgA antibodies to lipopolysaccharide. J Infect. 1992 May;24(3):257–261. [PubMed]
  • Chart H, Scotland SM, Rowe B. Serum antibodies to Escherichia coli serotype O157:H7 in patients with hemolytic uremic syndrome. J Clin Microbiol. 1989 Feb;27(2):285–290. [PMC free article] [PubMed]
  • Chart H, Smith HR, Scotland SM, Rowe B, Milford DV, Taylor CM. Serological identification of Escherichia coli O157:H7 infection in haemolytic uraemic syndrome. Lancet. 1991 Jan 19;337(8734):138–140. [PubMed]
  • Cohen A, Madrid-Marina V, Estrov Z, Freedman MH, Lingwood CA, Dosch HM. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol. 1990;2(1):1–8. [PubMed]
  • Dodds KL, Perry MB, McDonald IJ. Electrophoretic and immunochemical study of the lipopolysaccharides produced by chemostat-grown Escherichia coli O157. J Gen Microbiol. 1987 Sep;133(9):2679–2687. [PubMed]
  • Greatorex JS, Thorne GM. Humoral immune responses to Shiga-like toxins and Escherichia coli O157 lipopolysaccharide in hemolytic-uremic syndrome patients and healthy subjects. J Clin Microbiol. 1994 May;32(5):1172–1178. [PMC free article] [PubMed]
  • Griffin PM, Tauxe RV. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol Rev. 1991;13:60–98. [PubMed]
  • Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985 May;151(5):775–782. [PubMed]
  • Karmali MA, Petric M, Winkler M, Bielaszewska M, Brunton J, van de Kar N, Morooka T, Nair GB, Richardson SE, Arbus GS. Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli Vero cytotoxin 1. J Clin Microbiol. 1994 Jun;32(6):1457–1463. [PMC free article] [PubMed]
  • Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983 Mar 19;1(8325):619–620. [PubMed]
  • Levine MM, McEwen J, Losonsky G, Reymann M, Harari I, Brown JE, Taylor DN, Donohue-Rolfe A, Cohen D, Bennish M, et al. Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery. J Clin Microbiol. 1992 Jul;30(7):1636–1641. [PMC free article] [PubMed]
  • Lingwood CA, Law H, Richardson S, Petric M, Brunton JL, De Grandis S, Karmali M. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem. 1987 Jun 25;262(18):8834–8839. [PubMed]
  • Lopez EL, Diaz M, Devoto S, Grinstein S, Woloj M, Murray BE, Rubeglio E, Mendilaharzu F, Turco M, Vasquez M, et al. Evidence of infection with organisms producing Shiga-like toxins in household contacts of children with the hemolytic uremic syndrome. Pediatr Infect Dis J. 1991 Jan;10(1):20–24. [PubMed]
  • Lopez EL, Diaz M, Grinstein S, Devoto S, Mendilaharzu F, Murray BE, Ashkenazi S, Rubeglio E, Woloj M, Vasquez M, et al. Hemolytic uremic syndrome and diarrhea in Argentine children: the role of Shiga-like toxins. J Infect Dis. 1989 Sep;160(3):469–475. [PubMed]
  • Notenboom RH, Borczyk A, Karmali MA, Duncan LM. Clinical relevance of a serological cross-reaction between Escherichia coli O157 and Brucella abortus. Lancet. 1987 Sep 26;2(8561):745–745. [PubMed]
  • Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, Kobayashi JM. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis. 1989 Dec;160(6):994–998. [PubMed]
  • Pai CH, Ahmed N, Lior H, Johnson WM, Sims HV, Woods DE. Epidemiology of sporadic diarrhea due to verocytotoxin-producing Escherichia coli: a two-year prospective study. J Infect Dis. 1988 May;157(5):1054–1057. [PubMed]
  • Perry MB, Bundle DR. Antigenic relationships of the lipopolysaccharides of Escherichia hermannii strains with those of Escherichia coli O157:H7, Brucella melitensis, and Brucella abortus. Infect Immun. 1990 May;58(5):1391–1395. [PMC free article] [PubMed]
  • Perry MB, Bundle DR, MacLean L, Perry JA, Griffith DW. The structure of the antigenic lipopolysaccharide O-chains produced by Salmonella urbana and Salmonella godesberg. Carbohydr Res. 1986 Nov 15;156:107–122. [PubMed]
  • Pirro F, Wieler LH, Failing K, Bauerfeind R, Baljer G. Neutralizing antibodies against Shiga-like toxins from Escherichia coli in colostra and sera of cattle. Vet Microbiol. 1995 Feb;43(2-3):131–141. [PubMed]
  • Riley LW, Remis RS, Helgerson SD, McGee HB, Wells JG, Davis BR, Hebert RJ, Olcott ES, Johnson LM, Hargrett NT, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med. 1983 Mar 24;308(12):681–685. [PubMed]
  • Siddons CA, Chapman PA. Detection of serum and faecal antibodies in haemorrhagic colitis caused by Escherichia coli O157. J Med Microbiol. 1993 Dec;39(6):408–415. [PubMed]
  • Thomas A, Smith HR, Rowe B. Use of digoxigenin-labelled oligonucleotide DNA probes for VT2 and VT2 human variant genes to differentiate Vero cytotoxin-producing Escherichia coli strains of serogroup O157. J Clin Microbiol. 1993 Jul;31(7):1700–1703. [PMC free article] [PubMed]
  • Wilson JB, McEwen SA, Clarke RC, Leslie KE, Wilson RA, Waltner-Toews D, Gyles CL. Distribution and characteristics of verocytotoxigenic Escherichia coli isolated from Ontario dairy cattle. Epidemiol Infect. 1992 Jun;108(3):423–439. [PMC free article] [PubMed]
  • Yamada S, Kai A, Kudoh Y. Serodiagnosis by passive hemagglutination test and verotoxin enzyme-linked immunosorbent assay of toxin-producing Escherichia coli infections in patients with hemolytic-uremic syndrome. J Clin Microbiol. 1994 Apr;32(4):955–959. [PMC free article] [PubMed]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...